The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Open accessAbstract
Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital. Design Prospective observational study. Setting Two large general hospitals in Merseyside, England. Participants 18 820 patients aged > 16 years admitted over six months and assessed for cause of admission. Main outcome measures Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome. Results There were 1225 admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is £466m (€706m, $847m). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding. Conclusion The burden of ADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Cited by
Adverse drug reactions in special populations – the elderly
Davies, E. A., & O'Mahony, M. S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12596 · Cited by 604
Predicting risk of adverse drug reactions in older adults
Lavan, A. H., & Gallagher, P. (2016) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615615472 · Cited by 455
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Pound, P., & Ritskes-Hoitinga, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1678-1 · Cited by 419
An agenda for personalized medicine
Ng, P. C., Murray, S. S., Levy, S., & Venter, J. C. (2009) · Nature · doi:10.1038/461724a · Cited by 330
Ravn-Nielsen, L. V., Duckert, M.-L., Lund, M. L., Henriksen, J. P., Nielsen, M. L., Eriksen, C. S., Buck, T. C., Pottegård, A., Hansen, M. R., & Hallas, J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.8274 · Cited by 310
Methylxanthine Drug Monitoring with Wearable Sweat Sensors
Tai, L., Gao, W., Chao, M., Bariya, M., Ngo, Q. P., Shahpar, Z., Nyein, H. Y. Y., Park, H., Sun, J., Jung, Y., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707442 · Cited by 310
The future of drug safety testing: expanding the view and narrowing the focus
Stevens, J. L., & Baker, T. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.009 · Cited by 286
The clinical implications of ageing for rational drug therapy
Shi, S., Mörike, K., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0422-1 · Cited by 244
Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., & Park, B. K. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp235 · Cited by 223
Self-citationGruchalla, R. S., & Pirmohamed, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp043986 · Cited by 204
Self-citationHealthcare costs and utilization for Medicare beneficiaries with Alzheimer's
Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-108 · Cited by 196
Let’s talk about sex: Differences in drug therapy in males and females
Madla, C. M., Gavins, F. K. H., Merchant, H. A., Orlu, M., Murdan, S., & Basit, A. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.014 · Cited by 167
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Gagnon, M.-P., Nsangou, É.-R., Payne-Gagnon, J., Grenier, S., & Sicotte, C. (2014) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-002203 · Cited by 132
Bean, D. M., Wu, H., Iqbal, E., Dzahini, O., Ibrahim, Z. M., Broadbent, M., Stewart, R., & Dobson, R. J. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-16674-x · Cited by 127
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Meyer, P.-F., Tremblay-Mercier, J., Leoutsakos, J., Madjar, C., Lafaille-Maignan, M.-É., Savard, M., Rosa-Neto, P., Poirier, J., Etienne, P., Breitner, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007232 · Cited by 113
Nestoriuc, Y., von Blanckenburg, P., Schuricht, F., Barsky, A. J., Hadji, P., Albert, U.-S., & Rief, W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw266 · Cited by 103
Bruhn, H., Bond, C. M., Elliott, A. M., Hannaford, P. C., Lee, A. J., McNamee, P., Smith, B. H., Watson, M. C., Holland, R., & Wright, D. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002361 · Cited by 99
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Wu, L., Ingle, T., Liu, Z., Zhao-Wong, A., Harris, S., Thakkar, S., Zhou, G., Yang, J., Xu, J., Mehta, D., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2628-5 · Cited by 80
Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas
Parekh, T. M., Raji, M., Lin, Y.-L., Tan, A., Kuo, Y.-F., & Goodwin, J. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3293 · Cited by 75
Current perspectives on severe drug eruption
Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08859-0 · Cited by 60
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Grant, A. M., Guthrie, B., & Dreischulte, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004153 · Cited by 32
Abbas, A., Al-Shaibi, S., Sankaralingam, S., Awaisu, A., Kattezhathu, V. S., Wongwiwatthananukit, S., & Owusu, Y. B. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01346-8 · Cited by 29
Gastrointestinal safety pharmacology in drug discovery and development
Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_12 · Cited by 29
Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R. S., & Bhandari, M. (2021) · Pain Research and Management · doi:10.1155/2021/8857948 · Cited by 20
Kenna, J. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1290082 · Cited by 7
Metadata
- Authors
- Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-07-01
- Volume
- 329
- Issue
- 7456
- Pages
- 15-19
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1992746042
- Cited by
- 3,230
- References
- 1
- FWCI
- 104.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
